CO2021018155A2 - Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 - Google Patents
Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1Info
- Publication number
- CO2021018155A2 CO2021018155A2 CONC2021/0018155A CO2021018155A CO2021018155A2 CO 2021018155 A2 CO2021018155 A2 CO 2021018155A2 CO 2021018155 A CO2021018155 A CO 2021018155A CO 2021018155 A2 CO2021018155 A2 CO 2021018155A2
- Authority
- CO
- Colombia
- Prior art keywords
- positive allosteric
- allosteric modulator
- tetrahydroisoquinoline derivative
- substituted tetrahydroisoquinoline
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183643 | 2019-07-01 | ||
| PCT/EP2020/068183 WO2021001288A1 (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021018155A2 true CO2021018155A2 (es) | 2022-01-17 |
Family
ID=67137843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0018155A CO2021018155A2 (es) | 2019-07-01 | 2021-12-29 | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220259179A1 (https=) |
| EP (1) | EP3993794A1 (https=) |
| JP (1) | JP7510444B2 (https=) |
| KR (1) | KR20220029686A (https=) |
| CN (2) | CN117700395A (https=) |
| AR (1) | AR119318A1 (https=) |
| AU (1) | AU2020299953B2 (https=) |
| BR (1) | BR112021022378A2 (https=) |
| CA (1) | CA3139571A1 (https=) |
| CL (1) | CL2021002946A1 (https=) |
| CO (1) | CO2021018155A2 (https=) |
| EC (1) | ECSP21093559A (https=) |
| IL (2) | IL289314B2 (https=) |
| MA (1) | MA56440A (https=) |
| MX (2) | MX2021015873A (https=) |
| MY (1) | MY210361A (https=) |
| PE (1) | PE20221020A1 (https=) |
| PH (1) | PH12021552825A1 (https=) |
| SA (1) | SA521431279B1 (https=) |
| SG (1) | SG11202112537YA (https=) |
| TW (2) | TWI875776B (https=) |
| WO (1) | WO2021001288A1 (https=) |
| ZA (1) | ZA202109193B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2976784T3 (es) | 2020-10-07 | 2024-08-08 | Lilly Co Eli | Derivados de fenil-3,4-dihidroisoquinolin-2(1H)-il-etan-1-ona como moduladores alostéricos positivos del receptor de dopamina D1 |
| US20240083925A1 (en) | 2020-12-18 | 2024-03-14 | UCB Biopharma SRL | Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone |
| JP7798891B2 (ja) | 2020-12-18 | 2026-01-14 | ユーシービー バイオファルマ エスアールエル | Ｄ１陽性アロステリック調節因子としての置換テトラヒドロイソキノリン誘導体 |
| WO2022129267A1 (en) * | 2020-12-18 | 2022-06-23 | UCB Biopharma SRL | Amorphous solid dispersions |
| EP4304577A1 (en) * | 2021-03-09 | 2024-01-17 | Eli Lilly And Co. | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
| WO2026022198A1 (en) | 2024-07-25 | 2026-01-29 | UCB Biopharma SRL | Process for the preparation of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1 s,3 r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1 h-isoquinolin-2-yl]ethanone monohydrate |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2679735A1 (en) | 2007-03-01 | 2008-09-12 | Janssen Pharmaceutica N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
| KR101284796B1 (ko) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스 |
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| WO2016055479A1 (en) | 2014-10-08 | 2016-04-14 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
| CN108884050B (zh) * | 2016-04-13 | 2022-07-05 | Ucb生物制药私人有限公司 | 四氢异喹啉衍生物 |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
-
2020
- 2020-06-29 PH PH1/2021/552825A patent/PH12021552825A1/en unknown
- 2020-06-29 WO PCT/EP2020/068183 patent/WO2021001288A1/en not_active Ceased
- 2020-06-29 BR BR112021022378A patent/BR112021022378A2/pt unknown
- 2020-06-29 IL IL289314A patent/IL289314B2/en unknown
- 2020-06-29 AU AU2020299953A patent/AU2020299953B2/en active Active
- 2020-06-29 MY MYPI2021006862A patent/MY210361A/en unknown
- 2020-06-29 US US17/621,851 patent/US20220259179A1/en active Pending
- 2020-06-29 SG SG11202112537YA patent/SG11202112537YA/en unknown
- 2020-06-29 CN CN202311788931.8A patent/CN117700395A/zh active Pending
- 2020-06-29 PE PE2021002218A patent/PE20221020A1/es unknown
- 2020-06-29 JP JP2021577411A patent/JP7510444B2/ja active Active
- 2020-06-29 IL IL319939A patent/IL319939A/en unknown
- 2020-06-29 EP EP20734406.0A patent/EP3993794A1/en active Pending
- 2020-06-29 CN CN202080043657.XA patent/CN113993857B/zh active Active
- 2020-06-29 MA MA056440A patent/MA56440A/fr unknown
- 2020-06-29 CA CA3139571A patent/CA3139571A1/en active Pending
- 2020-06-29 KR KR1020227002600A patent/KR20220029686A/ko active Pending
- 2020-06-29 MX MX2021015873A patent/MX2021015873A/es unknown
- 2020-06-30 TW TW109122035A patent/TWI875776B/zh active
- 2020-06-30 AR ARP200101853A patent/AR119318A1/es unknown
- 2020-06-30 TW TW114104593A patent/TW202537959A/zh unknown
-
2021
- 2021-11-08 CL CL2021002946A patent/CL2021002946A1/es unknown
- 2021-11-17 ZA ZA2021/09193A patent/ZA202109193B/en unknown
- 2021-12-16 MX MX2024015493A patent/MX2024015493A/es unknown
- 2021-12-29 EC ECSENADI202193559A patent/ECSP21093559A/es unknown
- 2021-12-29 CO CONC2021/0018155A patent/CO2021018155A2/es unknown
- 2021-12-30 SA SA521431279A patent/SA521431279B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113993857B (zh) | 2024-01-02 |
| CN117700395A (zh) | 2024-03-15 |
| SG11202112537YA (en) | 2021-12-30 |
| CL2021002946A1 (es) | 2022-07-15 |
| US20220259179A1 (en) | 2022-08-18 |
| WO2021001288A1 (en) | 2021-01-07 |
| IL289314A (en) | 2022-02-01 |
| MX2021015873A (es) | 2022-02-03 |
| IL289314B1 (en) | 2025-05-01 |
| AU2020299953A1 (en) | 2022-01-06 |
| AR119318A1 (es) | 2021-12-09 |
| PE20221020A1 (es) | 2022-06-16 |
| EP3993794A1 (en) | 2022-05-11 |
| JP2022539152A (ja) | 2022-09-07 |
| KR20220029686A (ko) | 2022-03-08 |
| MY210361A (en) | 2025-09-13 |
| ECSP21093559A (es) | 2022-02-25 |
| TWI875776B (zh) | 2025-03-11 |
| IL289314B2 (en) | 2025-09-01 |
| PH12021552825A1 (en) | 2022-10-03 |
| TW202115010A (zh) | 2021-04-16 |
| WO2021001288A9 (en) | 2021-09-02 |
| MX2024015493A (es) | 2025-02-10 |
| JP7510444B2 (ja) | 2024-07-03 |
| CA3139571A1 (en) | 2021-01-07 |
| MA56440A (fr) | 2022-05-11 |
| SA521431279B1 (ar) | 2024-01-09 |
| IL319939A (en) | 2025-05-01 |
| TW202537959A (zh) | 2025-10-01 |
| CN113993857A (zh) | 2022-01-28 |
| AU2020299953B2 (en) | 2025-06-05 |
| BR112021022378A2 (pt) | 2022-03-08 |
| ZA202109193B (en) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21093559A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| CL2023001369A1 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| UY35818A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| BR112016000909A8 (pt) | derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas | |
| CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
| MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| MX2017006382A (es) | Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer. | |
| UY35469A (es) | Moduladores de p2x7 | |
| CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
| MX2024007938A (es) | Indoles, indazoles y analogos relacionados para inhibir yap/taz-tead. | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) | |
| MX2024007929A (es) | Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead. | |
| CO2025003099A2 (es) | Compuestos para el tratamiento del cáncer | |
| ECSP22007557A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| ECSP23041779A (es) | Un derivado de tetrahidroisoquinolina sustituido como un modulador alostérico positivo de d1 | |
| ECSP24007534A (es) | Inhibidores de transglutaminasas | |
| MX2019014436A (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa. | |
| UY38072A (es) | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |